These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 31715085)

  • 1. Off-label use of intravenous antimicrobials for inhalation in patients with cystic fibrosis.
    McKinzie CJ; Chen L; Ehlert K; Grisso AG; Linafelter A; Lubsch L; O'Brien CE; Pan AC; Wright BA; Elson EC
    Pediatr Pulmonol; 2019 Nov; 54 Suppl 3():S27-S45. PubMed ID: 31715085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin.
    Ehsan Z; Clancy JP
    Future Microbiol; 2015; 10(12):1901-12. PubMed ID: 26573178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
    Greally P; Whitaker P; Peckham D
    Curr Med Res Opin; 2012 Jun; 28(6):1059-67. PubMed ID: 22401602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nebulized gentamicin in combination with systemic antibiotics for eradicating early Pseudomonas aeruginosa infection in children with cystic fibrosis.
    Van Stormbroek B; Zampoli M; Morrow BM
    Pediatr Pulmonol; 2019 Apr; 54(4):393-398. PubMed ID: 30656856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis.
    Høiby N
    BMC Med; 2011 Apr; 9():32. PubMed ID: 21463524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous infusion meropenem and ticarcillin-clavulanate in pediatric cystic fibrosis patients.
    Zobell JT; Ferdinand C; Young DC
    Pediatr Pulmonol; 2014 Mar; 49(3):302-6. PubMed ID: 23775821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.
    Cantón R; Cobos N; de Gracia J; Baquero F; Honorato J; Gartner S; Alvarez A; Salcedo A; Oliver A; García-Quetglas E;
    Clin Microbiol Infect; 2005 Sep; 11(9):690-703. PubMed ID: 16104983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managing Pseudomonas aeruginosa respiratory infections in cystic fibrosis.
    Langan KM; Kotsimbos T; Peleg AY
    Curr Opin Infect Dis; 2015 Dec; 28(6):547-56. PubMed ID: 26524327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy and safety of aerosolized tobramycin 300 mg/4 ml in cystic fibrosis.
    Mazurek H; Chiron R; Kucerova T; Geidel C; Bolbas K; Chuchalin A; Blanco-Aparicio M; Santoro D; Varoli G; Zibellini M; Cicirello HG; Antipkin YG
    Pediatr Pulmonol; 2014 Nov; 49(11):1076-89. PubMed ID: 24464974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis.
    Cheer SM; Waugh J; Noble S
    Drugs; 2003; 63(22):2501-20. PubMed ID: 14609360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization of colistin dosing regimen for cystic fibrosis patients with chronic Pseudomonas aeruginosa biofilm lung infections.
    Hengzhuang W; Green K; Pressler T; Skov M; Katzenstein TL; Wu X; Høiby N
    Pediatr Pulmonol; 2019 May; 54(5):575-580. PubMed ID: 30803159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Use of inhaled tobramycin in patients with cystic fibrosis].
    Chermenskiĭ AG; Gembitskaia TE
    Ter Arkh; 2010; 82(8):76-8. PubMed ID: 20873251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhaled antibiotics in cystic fibrosis: a review.
    Toso C; Williams DM; Noone PG
    Ann Pharmacother; 1996; 30(7-8):840-50. PubMed ID: 8826569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients.
    Stuart Elborn J; Geller DE; Conrad D; Aaron SD; Smyth AR; Fischer R; Kerem E; Bell SC; Loutit JS; Dudley MN; Morgan EE; VanDevanter DR; Flume PA
    J Cyst Fibros; 2015 Jul; 14(4):507-14. PubMed ID: 25592656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [TOBI Podhaler for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis patients].
    Pierart F
    Rev Med Liege; 2013 Sep; 68(9):486-8. PubMed ID: 24180205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal airway antimicrobial therapy for cystic fibrosis: the role of inhaled aztreonam lysine.
    Elborn JS; Henig NR
    Expert Opin Pharmacother; 2010 Jun; 11(8):1373-85. PubMed ID: 20426707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study.
    Tiddens HA; De Boeck K; Clancy JP; Fayon M; H G M A; Bresnik M; Derchak A; Lewis SA; Oermann CM;
    J Cyst Fibros; 2015 Jan; 14(1):111-9. PubMed ID: 25091537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical applications of pulmonary delivery of antibiotics.
    Flume PA; VanDevanter DR
    Adv Drug Deliv Rev; 2015 May; 85():1-6. PubMed ID: 25453268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial susceptibility of Pseudomonas aeruginosa before and after initiation of inhaled tobramycin in Bulgaria.
    Petrova G; Strateva T; Miteva D; Lazova S; Perenovska P
    J Infect Dev Ctries; 2016 Nov; 10(11):1265-1267. PubMed ID: 27886041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Inhaled Antimicrobial Formulations for Use in the Cystic Fibrosis Patient Population.
    Campbell CT; McCaleb R; Manasco KB
    Ann Pharmacother; 2016 Feb; 50(2):133-40. PubMed ID: 26692274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.